Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 150.34M P/E - EPS this Y 16.90% Ern Qtrly Grth -
Income -101.35M Forward P/E -1.35 EPS next Y -6.50% 50D Avg Chg -17.00%
Sales 409k PEG - EPS past 5Y - 200D Avg Chg -64.00%
Dividend N/A Price/Book 0.90 EPS next 5Y - 52W High Chg -87.00%
Recommedations 2.10 Quick Ratio 11.08 Shares Outstanding 71.07M 52W Low Chg 3.00%
Insider Own 0.80% ROA -34.10% Shares Float 70.54M Beta 0.07
Inst Own 60.90% ROE -63.29% Shares Shorted/Prior 21.87M/21.70M Price 3.05
Gross Margin - Profit Margin - Avg. Volume 1,814,804 Target Price 20.57
Oper. Margin -534,900.00% Earnings Date Nov 5 Volume 986,970 Change -3.79%
About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc. News
11/15/24 Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
11/14/24 Altimmune Third Quarter 2024 Earnings: Beats Expectations
11/12/24 Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/11/24 Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11/24 Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
11/07/24 Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
11/06/24 Altimmune to Participate at Two Upcoming Investor Conferences
11/04/24 Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
10/15/24 Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
10/01/24 Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
09/30/24 Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
09/10/24 CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
09/10/24 Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
09/03/24 Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
08/10/24 Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
08/07/24 CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
08/01/24 With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing
08/01/24 Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
07/25/24 Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
ALT Chatroom

User Image JohnFromLongRobust Posted - 45 minutes from now

$ALT Would be nice to bounce over 8 tmr

User Image Lazarus2024 Posted - 40 minutes from now

$ALT Monday morning pre-market partnership news🙏

User Image Braveheart_13 Posted - 20 minutes from now

$ALT Patently false. They aren't going to waste 6 months inking a partnership. If it's a partnership and not an outright BO, you can bet your bottom dollar that big pharma will be clawing to be the first to secure rights to pemvi

User Image golfeveryday Posted - 5 minutes from now

$ALT https://www.clearygottlieb.com/-/media/files/clearys-pharma-bites/clearys-pharma-bites-contingent-value-rights-in-pharma-deals.pdf

User Image Psyclist Posted - 15 minutes ago

$ALT fatty liver and testosterone augmentation… if only there was an option that could resolve both fatty liver and lean body mass loss...

User Image GreenEnergy2022 Posted - 39 minutes ago

$ALT Before end of December imo. Now as phs3 design is approved, BP`s who is interested need to move fast so no any other BP will sign the deal before them.

User Image Investor202311 Posted - 42 minutes ago

$ALT - There will not be any M&A deals till 2025Q2. Any patnership for Obesity will happen in 2025 Q1. MASH results from P2 trial could change valuation.

User Image Franchescobio Posted - 47 minutes ago

$ALT Simple poll: Vote on the following question. a) Altimmune will be $20 before Christmas. b) Altimmune will be between $15-20 before Christmas. c) Altimmune will be under $10 before Christmas.

User Image erik2829 Posted - 51 minutes ago

$ALT lets goooooooooo

User Image GreenEnergy2022 Posted - 57 minutes ago

$ALT GLP1 & beyond weight loss, as new data and knowledge in the space evolves: - Heart health, study done by scientists at University College London: https://www.ucl.ac.uk/news/2024/may/weight-loss-drug-semaglutide-linked-better-heart-health - A study of nearly 84,000 patients published in Nature showed that weight loss medications reduced the risk of developing or relapsing into alcohol use disorders by over 50 percent: https://www.nature.com/articles/s41467-024-48780-6 - Sleep apnea. The study showed a 55 percent reduction in symptoms in those who used tirzepatide, writes Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds - Alzheimer's. A recent study published in the journal Alzheimer's & Dementia analyzed health data from over a million people with type 2 diabetes. The results showed that those who used GLP-1 drugs had a 40 to 70 percent lower risk of developing Alzheimer's disease. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313

User Image Stinger2023 Posted - 1 hour ago

$ALT this last 2 days was more of a programmed manufactured selling allowing some big shorts to cover or allowing for accumulation by some fund. Plus, the weekly calls got killed.

User Image Lazarus2024 Posted - 1 hour ago

$ALT A lot of buying but PPS was pressured down.🤔

User Image BTECHINV Posted - 1 hour ago

$ALT What % of GLP1 investors could answer Q 1-12? 1. What disease is leader in global all-cause-mortality? 2. What is the fastest growing cause of Liver transplantation in the US? 3. What is metabolic health? 4. Which Fat type is most concerning medically and why? 5. What % LEAN tissue WL is common with current GLP1 & GIPs? How does that compare to rigorous diet & exercise? 6. What are BMR & Thermogenesis? 7. Name 5 potential OB co-morbidities. 8. How many major classes of GLP-1's are currently approved, describe their mechanisms of action? What is GCGr & its MOA? 9. What is the gold standard technique for measuring body fat (aka body comp. analysis)? Describe its purpose and importance. 10. Was Glucagon discovered before or after the year 2000? What has been its most common use to-date and why? 11. Describe physiological Glucagon vs. pharmacological Glucagon. 12. What typically drives Tolerability improvements in a P3 trial design? Disclosure: Long Alt, not investment/med advice

User Image 7Bstmde7B Posted - 1 hour ago

$ALT now this guy has the answer!!

User Image GSP Posted - 1 hour ago

Trading Watch List Video for November 18th (part 3): $HIMS $ALT $AMZN $VKTX $SMCI Watch here: https://greatstockpix.com/november-18th-day-trading-watch-list/ .

User Image 7Bstmde7B Posted - 1 hour ago

$ALT Joking. The issue is very complex and dynamic in the USA. What we need to worry about are policies (or lack of) that lend to far toward the problems we have addressing themselves. Our culture, our workplace environment does not lend toward this as a solution. We work our asses off to make this country great, more so than other countries, and as the economy became more reliant on desk jobs, a result of this is obesity. It is a dichotomy that I can only hope those in charge understand! One thing I do know is that PemVi is a much, much better alternative… Bullish

User Image NGEA Posted - 1 hour ago

$ALT https://www.cbinsights.com/research-cb-insights-vs-crunchbase?campaignid=1740638586&adgroupid=120215105956&utm_term=crunchbase&utm_source=google&utm_medium=cpc&utm_campaign=PAID_GOOGLE_COMPETITOR&utm_content=google-competitors-crunchbase&hsa_tgt=kwd-9814158800&hsa_grp=120215105956&hsa_src=g&hsa_net=adwords&hsa_mt=e&hsa_ver=3&hsa_ad=654531625086&hsa_acc=5728918340&hsa_kw=crunchbase&hsa_cam=1740638586&gad_source=1&gclid=CjwKCAiAxea5BhBeEiwAh4t5K7YGAuzjx1-gbhrp_FWYbYoWQkfoQg-fiVp7dBpR146rFp-yL3hZzRoC5-8QAvD_BwE

User Image 7Bstmde7B Posted - 1 hour ago

$ALT All this complaining about the cost of food, the answer is to stop producing cheaper foods (and excercise!). Other countries, good countries, HUGE, GREAT countries have much higher food costs (see EUROPE!) and it is not a problem for them! These GREAT countries seem to afford it AND stay in PERFECT HEALTH!

User Image MineMineItsAllMine Posted - 1 hour ago

$ALT A little over a month ago, @thaines1 posted the following: Oct 09, 2024 9:38 AM $ALT "How many shares do we have as retail on here collectively I wonder?" People started posting and I decided to total those numbers. Occasionally, people have continued to post their totals and I have updated or added as the case may be. I am sure that I have missed some posts. As of 9:45 AM CT 11-17-2024 For the 75 people who have posted shares that they own, we collectively have 3,501,582 shares. Source: Form 10-Q For the quarterly period ended September 30, 2024 Outstanding 71,124,407 Common stock warrants 0 Common stock options 6,435,016 Restricted stock units 784,227 Restricted stock 0 TOTAL 78,343,650 This results in this percent of ownership: - 4.92% as a % of shares Outstanding - 4.47% as a % of shares TOTAL

User Image mrdan321 Posted - 2 hours ago

$ALT Looking for anyone else to confirm this claim.

User Image TraderMason Posted - 2 hours ago

$ALT Americans aren’t going to magically stop eating McDonalds just because RFK took office. Just like how pharmaceutical companies aren’t going to magically stop selling drugs. This whole RFK thing is so overblown, it’s fucking ridiculous. RFK just wants drugs/vaccines to be safer and companies to be more transparent and liable for negligence. That’s it.

User Image GreenEnergy2022 Posted - 2 hours ago

$ALT Prediction for the coming week: 9,5 by EOD XBI/Biotech sector with overreaction last week(oversold). Watch out for a sudden upward movement the coming week. We have a lot watchers here/swing traders who will buy in once the bounce starts.

User Image 7Bstmde7B Posted - 2 hours ago

$ALT can someone with the ability, do a parody of Trump and Musk pigging out on chicken nuggies, fries, and large cokes with RFK handing them a bottle of PemVi…shit will make us viral! post it hear, on reddit, etc.

User Image Androach Posted - 2 hours ago

$ALT We have almost as many watchers as Carvana right now. That seems crazy to me. A LOT of eyes have front row seats to whatever happens next.

User Image 7Bstmde7B Posted - 2 hours ago

$ALT tomorrow

User Image Franchescobio Posted - 2 hours ago

$ALT X10 very soon

User Image Franchescobio Posted - 2 hours ago

$ALT Elon Musk: Making GLP inhibitors available at low cost to Americans who wish to use them would greatly improve health and reduce healthcare costs

User Image Excessive_Directive Posted - 2 hours ago

$ALT All of this RFK talk really does is push pemvidutide and it's highly differentiated effects all the way to the top. Pemvidutide is the solution to the problem of the "weightloss only" drugs.

User Image SteeCo Posted - 3 hours ago

@Redsworld90 I’ll tell you what: I’d rather take 60+ now than wait another 3-4 years to reach 60+… you can take your money and invest in another tenbagger like $HIMS or $ALT or whatever you think will do and make much more money in that time period than just doubling or tripling… plus don’t forget inflation. 60 three years ago was something very different than 60 now. Think about it! Time is money never forget that

User Image 7Bstmde7B Posted - 3 hours ago

$ALT The whole ”people can just exercise” is a joke. Our country will be led by people who chose to work, not have to work, and while this is noble, finding time to do anything outside of working and family for 99% of the population, without jeopardizing either, is an impossibility. Particularly when we have been ingrained with the message you must work hard (meaning mostly in a chair, these days) to succeed. bezos, musk, trump, all rely on people to work countless hours at the expense of health and family, for them to succeed. Me, I love to work, do better than most, have a family, but if I exercised, would have to give up family or risk losing my preferred status on that ladder. I represent the top tier of the 99% and can honestly say, only the douches with an innate ability to talk their way to the too without doing much, have time to exercise. PemVi for me!

Analyst Ratings
B. Riley Securities Buy Aug 12, 24
B. Riley Securities Buy Jun 25, 24
Piper Sandler Overweight Jun 21, 24
HC Wainwright & Co. Buy May 14, 24
JMP Securities Market Outperform May 10, 24
Guggenheim Neutral Apr 29, 24
HC Wainwright & Co. Buy Apr 1, 24
B. Riley Securities Buy Mar 28, 24
B. Riley Securities Buy Feb 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Drutz David Director Director Aug 15 Buy 2.875 300 862 29,785 08/15/23
GILL JOHN Director Director Aug 12 Sell 15.00 2,714 40,710 2,771 07/06/23
Drutz David Director Director Mar 23 Buy 4.27 9,000 38,430 29,484 03/27/23
Eisenstadt Richard I Chief Financial Offi.. Chief Financial Officer Mar 24 Buy 4.314 10,000 43,140 22,010 03/24/23
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Mar 23 Buy 4.22 10,000 42,200 33,311 03/23/23
Garg Vipin K President and CEO President and CEO Aug 12 Sell 15.0593 15,000 225,890 259,804 08/12/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jul 01 Option 2.83 27,769 78,586 18,487 07/05/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jul 01 Sell 12 37,164 445,968 8,305 07/05/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jun 27 Option 2.26 37,352 84,416 55,052 06/28/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jun 27 Sell 12 37,352 448,224 17,700 06/28/22
Drutz David Director Director Jun 15 Buy 8.00 1,000 8,000 20,012 06/16/22
Drutz David Director Director May 24 Buy 4.50 1,200 5,400 19,012 05/25/22
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Feb 28 Option 1.92 30,000 57,600 41,545 03/02/22
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Feb 28 Sell 7.52 30,000 225,600 11,545 03/02/22
Drutz David Director Director Jan 25 Option 2.4 70 168 17,882 01/26/22
Hodges Philip Director Director Dec 02 Sell 12.77 3,727 47,594 12/02/20